TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2025 Earnings Call Transcript March 5, 2026 TriSalus Life Sciences, Inc. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.13.

Overview of secondary liver cancer care pathways, key treatment steps, and the situations where dendritic cell treatment may be discussed as a selected option.

Milestone marks the commercial use of the first and only liquid embolic approved for hypervascular tumor embolization supported by a prospective, randomized, controlled clinical trial Instylla, Inc., ...

JACKSONVILLE, Fla. — A local hospital is using new technology to remove liver cancer without invasive surgery. It’s a word that no one ever wants to hear. “He found the cancer,” Paul Montgomery said.

OBJECTIVE: Preoperative embolization of paragangliomas decreases tumor volume and reduces intraoperative blood loss. This study aimed to evaluate the effect of the rate of devascularization achieved ...

In a recent pilot study, researchers tested the feasibility and effects of a 12-week home-based resistance training program. Their target patient population was children who have had a liver ...

We present the case of an 82-year-old woman with progressive dyspnea, hoarseness, and dysphagia due to a large substernal multinodular goiter. Ultrasound and CT revealed a predominantly left-lobe ...

PALM SPRINGS, Calif. (KESQ) - Embolization is an innovative option to treat internal hemorrhoids that avoids surgery. News Channel 3 talked with Dr. Sonny Bagla with IR Centers at Urologic Institute ...

There was no correlation between inlet flow rate and EEI. Instead, EEI exhibited an inverse linear relationship with target pressure, declining until flow cessation at a certain pressure greater than ...